fbpx

Advanced Colorectal Cancer

Adenocarcinoma of the Caecum

Male, 53 years

Patient Internal ID: 1183858059

ICD-10 code

C18.0 Malignant Neoplasm of Caecum

Diagnosis (Incl. Metastases/Stage) and Year

November 2019
Adenocarcinoma of the Caecum, Stage 4, KRAS +, Peritoneal and Liver Metastasis.

Previous Treatment

Chemotherapy (Oxaliplatin and Capecitabine) + Target Therapy (Bevacizumab), Surgery, Chemotherapy (De Gramont scheme) + Target Therapy (Aflibercept), Chemotherapy (Capecitabine).

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of Advanced Colorectal Cancer ~24 months from diagnosis. 5-year relative survival rates for Advanced Colon Cancer are 13%.

Treatment Provided

Allogeneic Umbilical Cord Blood Derived NK Cells (4 doses) over a period of 1 month and Xenogeneic Preventive and Therapeutic Anti-Cancer Vaccine (PTAC) (10 vaccines).

Patient Survival/Condition and Year
Date of Review: 16/02/2024

The patient has survived for 42 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy, Surgery and Target Therapy, has extended patient survival by an estimate of around 18 months.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.